Neutralising antibodies to certolizumab pegol do not appear to impact on efficacy or safety in patients with crohn's disease

被引：0
|
作者：
Nesbitt, A. M. [1 ]
Stephens, S. [2 ]
Bloomfield, R. [3 ]
机构：
[1] UCB, Antibody Biol Div, Slough, Berks, England
[2] UCB, Clin Assay Dept, Slough, Berks, England
[3] UCB, Slough, Berks, England
来源：
GUT | 2008年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
372
引用
收藏
页码：A142 / A142
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of certolizumab pegol do not appear to be affected by neutralizing antibodies in patients with Crohn's disease
    Stephens, Sue
    Bloomfield, Ralph
    Devine, Donna M.
    Nesbitt, Andrew M.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 : S475 - S475
  • [2] Neutralizing antibodies to certolizumab pegol do not appear to affect efficacy and safety in patients with Crohn's disease
    Stephens, S.
    Bloomfield, R.
    Devine, D.
    Nesbitt, A.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (01) : S27 - S27
  • [3] Efficacy of Certolizumab Pegol Therapy in Patients With Crohn's Disease
    Shafran, Ira
    Al-Maani, Sayel
    Burgunder, Patricia
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S451 - S451
  • [4] Efficacy and safety of certolizumab pegol for Crohn's disease in clinical practice
    Moon, W.
    Pestana, L.
    Becker, B.
    Loftus, E. V., Jr.
    Hanson, K. A.
    Bruining, D. H.
    Tremaine, W. J.
    Kane, S. V.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (04) : 428 - 440
  • [5] Antibodies to infliximab in patients with Crohn's disease do not cross-react with certolizumab pegol
    Vetterlein, O.
    Kopotsha, T. M.
    Nesbitt, A. M.
    Brown, D. T.
    Stephens, S.
    GUT, 2007, 56 : A116 - A116
  • [6] Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease
    Shao, L. -M.
    Chen, M. -Y.
    Chen, Q. -Y.
    Cai, J. -T.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 29 (06) : 605 - 614
  • [7] Efficacy of certolizumab pegol therapy in patients with Crohn's disease.
    Shafran, I
    Al-Maani, S.
    Burgunder, P.
    INFLAMMATORY BOWEL DISEASES, 2011, 17 : S62 - S62
  • [8] Editorial: long-term safety and efficacy of certolizumab pegol for Crohn's disease
    Cesarini, M.
    Danese, S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (10) : 1243 - 1243
  • [9] Certolizumab pegol in Crohn's disease
    Blick, Stephanie K. A.
    Curran, Monique P.
    BIODRUGS, 2007, 21 (03) : 195 - 201
  • [10] Antibodies to certolizumab pegol in patients with Crohn's disease do not cross-react with adalimumab, etanercept, or infliximab
    Vetterlein, Olivia M.
    Nesbitt, Andrew M.
    Stephens, Sue
    GASTROENTEROLOGY, 2007, 132 (04) : A556 - A556
12345